Abstract

DNA repair defects underlie many cancer syndromes. We tested whether de novo germline mutations (DNMs) are increased in families with germline defects in polymerase proofreading or base excision repair. A parent with a single germline POLE or POLD1 mutation, or biallelic MUTYH mutations, had 3-4 fold increased DNMs over sex-matched controls. POLE had the largest effect. The DNMs carried mutational signatures of the appropriate DNA repair deficiency. No DNM increase occurred in offspring of MUTYH heterozygous parents. Parental DNA repair defects caused about 20–150 DNMs per child, additional to the ~60 found in controls, but almost all extra DNMs occurred in non-coding regions. No increase in post-zygotic mutations was detected, excepting a child with bi-allelic MUTYH mutations who was excluded from the main analysis; she had received chemotherapy and may have undergone oligoclonal haematopoiesis. Inherited DNA repair defects associated with base pair-level mutations increase DNMs, but phenotypic consequences appear unlikely.

DNA repair defects underlie many cancer syndromes. This study investigates whether parents with inherited problems of DNA repair pass on an increased number of de novo mutations to their children. The authors find that this does occur, but that clinical consequences are unlikely.

Details

Title
Germline de novo mutations in families with Mendelian cancer syndromes caused by defects in DNA repair
Author
Sherwood, Kitty 1   VIAFID ORCID Logo  ; Ward, Joseph C. 2 ; Soriano, Ignacio 2   VIAFID ORCID Logo  ; Martin, Lynn 3 ; Campbell, Archie 4   VIAFID ORCID Logo  ; Rahbari, Raheleh 5   VIAFID ORCID Logo  ; Kafetzopoulos, Ioannis 1 ; Sproul, Duncan 1 ; Green, Andrew 6 ; Sampson, Julian R. 7 ; Donaldson, Alan 8 ; Ong, Kai-Ren 9   VIAFID ORCID Logo  ; Heinimann, Karl 10 ; Nielsen, Maartje 11   VIAFID ORCID Logo  ; Thomas, Huw 12 ; Latchford, Andrew 12 ; Palles, Claire 3   VIAFID ORCID Logo  ; Tomlinson, Ian 2   VIAFID ORCID Logo 

 Institute of Genomics and Cancer, Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Edinburgh, UK (GRID:grid.470904.e) (ISNI:0000 0004 0496 2805) 
 University of Oxford, Dept of Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Birmingham Medical School, Institute of Cancer and Genomic Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486) 
 Western General Hospital, Centre for Genetics and Experimental Medicine, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.417068.c) (ISNI:0000 0004 0624 9907) 
 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382) 
 Children’s Health Ireland and School of Medicine University College, Department of Clinical Genetics, Dublin, Ireland (GRID:grid.7886.1) (ISNI:0000 0001 0768 2743) 
 Cardiff University School of Medicine, Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff, UK (GRID:grid.5600.3) (ISNI:0000 0001 0807 5670) 
 St Michael’s Hospital, Bristol Regional Clinical Genetics Service, Bristol, UK (GRID:grid.470169.d) 
 Birmingham Women’s and Children’s NHS Foundation Trust, West Midlands Regional Genetics Service, Birmingham, UK (GRID:grid.498025.2) (ISNI:0000 0004 0376 6175) 
10  University Hospital Basel, Institute for Medical Genetics and Pathology, Basel, Switzerland (GRID:grid.410567.1) (ISNI:0000 0001 1882 505X) 
11  Leiden University Medical Centre, Department of Clinical Genetics, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
12  St Mark’s Hospital, Harrow, UK (GRID:grid.416510.7) 
Pages
3636
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2827366635
Copyright
© The Author(s) 2023. corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.